While China has been slower than several other countries in approving COVID-19 vaccines, it has been inoculating some citizens for months with three different shots still undergoing late-stage trials. "China's approval could boost the credibility of the vaccine," said Dong-yan Jin, a professor at the University of Hong Kong. "But if the vaccine wants to take a share in the global market, especially in developed countries, more data is necessary." A Sinopharm executive told a briefing detailed data would be released later and published in scientific journals at home and abroad. The price of the vaccine would depend on the scale of use, but the "premise" was that it would be free for the public in China, he said.

Source: bd News24 December 31, 2020 05:15 UTC